Patents by Inventor Josef Platzer
Josef Platzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399396Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of TL-2 and TL-21.Type: ApplicationFiled: August 11, 2022Publication date: December 14, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
-
Publication number: 20230332175Abstract: Herein is reported a transgenic vector comprising a humanized light chain locus, wherein said humanized light chain locus comprises (a) a V gene segment derived from human light chain V segment IGKV1-39-01, (b) 3? proximal to said light chain gene segment a promoter, and (c) 5? proximal to said light chain gene segment at least a fragment of the human IGKJ4 J-element.Type: ApplicationFiled: November 2, 2022Publication date: October 19, 2023Applicant: Hoffmann-La Roche Inc.Inventor: Josef Platzer
-
Publication number: 20210347916Abstract: Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N-terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the first part of the binding domain and the second part of the binding domain are associated with each other and form a binding site that specifically binds to a target.Type: ApplicationFiled: June 25, 2021Publication date: November 11, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Josef Platzer
-
Publication number: 20210062149Abstract: Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG+CD19+-B-cells, IgG+CD38+-B-cells, IgG+CD268+-B-cells, IgG?CD138+-B-cells, CD27+CD138+-B-cells or CD3?CD27+-B-cells. The method can comprise the step of incubating said B-cells at 37° C. for one hour in EL-4 B5 medium prior to the depositing step. The method can also comprise the step of centrifuging said single cell deposited B-cells prior to the co-cultivation. In the co-cultivation a feeder mix comprising interleukin-1beta, and tumor necrosis factor alpha and Staphylococcus aureus strain Cowans cells or BAFF or interleukin-2 and/or interleukin-10 and/or interleukin-6 and/or interleukin-4 can be used.Type: ApplicationFiled: June 12, 2020Publication date: March 4, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Josef ENDL, Natalie SCHUHMACHER, Sonja OFFNER, Josef PLATZER, Basile SIEWE, Irmgard THOREY
-
Publication number: 20200399341Abstract: Herein is reported a multimeric fusion polypeptide comprising five monomeric fusion polypeptides each comprising at least a Fab fragment and a COMP-domain of SEQ ID NO: 01 or a functional fragment thereof.Type: ApplicationFiled: April 29, 2020Publication date: December 24, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Guy Georges, Josef Platzer
-
Publication number: 20200325224Abstract: One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus cross-reactive antibody specifically binding to human CD3 epsilon of SEQ ID NO: 02 and specifically binding to a polypeptide of SEQ ID NO: 01, wherein the human cynomolgus cross-reactive antibody specifically binds to human and cynomolgus T cells, activates human T cells and does not bind to the same epitope as the antibody OKT3, the antibody UCHT1 and/or antibody the SP34.Type: ApplicationFiled: January 23, 2020Publication date: October 15, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg Tiefenthaler, Ekkehard Moessner, Valeria Lifke, Josef Platzer, Sonja Offner, Christiane Neumann, Mirko Ritter
-
Publication number: 20200299385Abstract: One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus cross-reactive antibody specifically binding to human CD3 epsilon of SEQ ID NO: 02 and specifically binding to a polypeptide of SEQ ID NO: 01, wherein the human cynomolgus cross-reactive antibody specifically binds to human and cynomolgus T cells, activates human T cells and does not bind to the same epitope as the antibody OKT3, the antibody UCHT1 and/or antibody the SP34.Type: ApplicationFiled: January 23, 2020Publication date: September 24, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg Tiefenthaler, Ekkehard Moessner, Valeria Lifke, Josef Platzer, Sonja Offner, Christiane Neumann, Mirko Ritter
-
Publication number: 20190389971Abstract: Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N-terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the first part of the binding domain and the second part of the binding domain are associated with each other and form a binding site that specifically binds to a target.Type: ApplicationFiled: November 1, 2018Publication date: December 26, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Josef Platzer
-
Publication number: 20190153091Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.Type: ApplicationFiled: October 3, 2018Publication date: May 23, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
-
Publication number: 20190100771Abstract: Herein is reported a transgenic vector comprising a humanized light chain locus, wherein said humanized light chain locus comprises (a) a V gene segment derived from human light chain V segment IGKV1-39-01, (b) 3? proximal to said light chain gene segment a promoter, and (c) 5? proximal to said light chain gene segment at least a fragment of the human IGKJ4 J-element.Type: ApplicationFiled: April 27, 2018Publication date: April 4, 2019Applicant: Hoffmann-La Roche Inc.Inventor: Josef Platzer
-
Publication number: 20180298335Abstract: Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG+CD19+-B-cells, IgG+CD38+-B-cells, IgG+CD268+-B-cells, IgG?CD138+-B-cells, CD27+CD138+-B-cells or CD3?CD27+-B-cells. The method can comprise the step of incubating said B-cells at 37° C. for one hour in EL-4 B5 medium prior to the depositing step. The method can also comprise the step of centrifuging said single cell deposited B-cells prior to the co-cultivation. In the co-cultivation a feeder mix comprising interleukin-1beta, and tumor necrosis factor alpha and Staphylococcus aureus strain Cowans cells or BAFF or interleukin-2 and/or interleukin-10 and/or interleukin-6 and/or interleukin-4 can be used.Type: ApplicationFiled: March 27, 2018Publication date: October 18, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Natalie Schuhmacher, Sonja Offner, Josef Platzer, Basile Siewe, Irmgard Thorey
-
Publication number: 20170233475Abstract: One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus cross-reactive antibody specifically binding to human CD3 epsilon of SEQ ID NO: 02 and specifically binding to a polypeptide of SEQ ID NO: 01, wherein the human cynomolgus cross-reactive antibody specifically binds to human and cynomolgus T cells, activates human T cells and does not bind to the same epitope as the antibody OKT3, the antibody UCHT1 and/or antibody the SP34.Type: ApplicationFiled: November 22, 2016Publication date: August 17, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Georg Tiefenthaler, Ekkehard Moessner, Valeria Lifke, Josef Platzer, Sonja Offner, Christiane Neumann, Mirko Ritter
-
Publication number: 20160251621Abstract: Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG+CD19+-B-cells, IgG+CD38+-B-cells, IgG+CD268+-B-cells, IgG?CD138+-B-cells, CD27+CD138+-B-cells or CD3?CD27+-B-cells. The method can comprise the step of incubating said B-cells at 37° C. for one hour in EL-4 B5 medium prior to the depositing step. The method can also comprise the step of centrifuging said single cell deposited B-cells prior to the co-cultivation. In the co-cultivation a feeder mix comprising interleukin-1beta, and tumor necrosis factor alpha and Staphylococcus aureus strain Cowans cells or BAFF or interleukin-2 and/or interleukin-10 and/or interleukin-6 and/or interleukin-4 can be used.Type: ApplicationFiled: May 6, 2016Publication date: September 1, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Natalie Schuhmacher, Sonja Offner, Josef Platzer, Basile Siewe, Irmgard Thorey
-
Publication number: 20140315252Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.Type: ApplicationFiled: November 21, 2012Publication date: October 23, 2014Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
-
Patent number: 8652842Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.Type: GrantFiled: February 27, 2013Date of Patent: February 18, 2014Assignee: Therapeutic Human Polyclonals, IncInventors: Josef Platzer, Roland Buelow, Wim van Schooten
-
Patent number: 8410333Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.Type: GrantFiled: July 29, 2009Date of Patent: April 2, 2013Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Roland Buelow, Wim van Schooten, Josef Platzer
-
Patent number: 8354568Abstract: The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression.Type: GrantFiled: March 17, 2011Date of Patent: January 15, 2013Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Roland Buelow, Josef Platzer
-
Publication number: 20110219465Abstract: The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression.Type: ApplicationFiled: March 17, 2011Publication date: September 8, 2011Inventors: Roland Buelow, Josef Platzer
-
Patent number: 7919672Abstract: The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression.Type: GrantFiled: August 2, 2006Date of Patent: April 5, 2011Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Roland Buelow, Josef Platzer
-
Patent number: RE47131Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.Type: GrantFiled: February 9, 2016Date of Patent: November 20, 2018Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Josef Platzer, Roland Buelow, Wim van Schooten